U.S. Capital Markets Stock News

NasdaqCM:LIDR
NasdaqCM:LIDRElectronic

Why AEye (LIDR) Is Up 20.4% After Shipping Apollo Lidar Sensors to Major Defense Customer

AEye, Inc. recently announced it started shipping its Apollo ultra-long-range lidar sensors to a leading U.S. defense contractor for enhanced wire detection in both manned and autonomous aircraft. This shipment highlights Apollo's software-defined flexibility and compact design, which enable customizable mission profiles and safer navigation in complex environments like urban and mountainous terrain. We'll explore how the rollout of Apollo’s configurable lidar solution to the defense sector...
NYSE:NVGS
NYSE:NVGSOil and Gas

Has Navigator Stock Pulled Back Too Far After Recent Volatility in 2025?

If you are wondering what to do with Navigator Holdings stock right now, you are not alone. Lately, this shipping specialist has delivered a bumpy ride for investors. After peaking earlier this year, the stock has pulled back by 8.6% over the past week and nearly 12.5% over the past month. Year-to-date, it is down 10.3%, erasing the steady gains that attracted attention in previous years. Still, it is worth remembering that Navigator Holdings remains up an impressive 81.8% over the last five...
NasdaqCM:ATYR
NasdaqCM:ATYRBiotechs

aTyr Pharma (ATYR): Evaluating Valuation Following New Efzofitimod Data and Securities Lawsuit

aTyr Pharma (ATYR) is drawing attention after presenting fresh Phase 3 results for its lead drug candidate, efzofitimod, at a major medical conference. The company also faces a newly filed securities class action lawsuit. See our latest analysis for aTyr Pharma. After a rocky stretch, aTyr Pharma’s recent ERS Congress presentation sparked renewed attention and contributed to a sharp 36.7% 7-day share price rebound, even as the stock remains down 72.9% this year. While the 1-year total...
NasdaqCM:UPXI
NasdaqCM:UPXIPersonal Products

Upexi (UPXI): Assessing Valuation as Investors Eye Digital Asset Showcase Presentation

Upexi (UPXI) is set to take the stage at the Digital Asset Treasury Showcase, where Chief Strategy Officer Brian Benjamin Rudick will present. Investors are watching closely for any signals on new initiatives or digital asset partnerships. See our latest analysis for Upexi. With excitement building around Upexi’s upcoming showcase, it is worth noting that after a strong 68% gain so far this year, recent share price momentum has cooled, giving back some ground over the past week but still...
NasdaqGM:ESPR
NasdaqGM:ESPRPharmaceuticals

Esperion Therapeutics (ESPR) Is Down 15.3% After Discounted $75M Equity Raise Will Dilution Redefine Its Growth Path?

Earlier this week, Esperion Therapeutics completed a public offering of 30 million shares of its common stock at US$2.50 per share, raising approximately US$75 million in gross proceeds. The offering was priced at a meaningful discount, enabling Esperion to fund the commercial expansion of its cholesterol drugs, development programs, and general operations. We'll now assess how this substantial equity raise and increased share count could influence Esperion's investment narrative and future...